Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

GNTA 10.23.2024

SERA-AI Powered Highlights
Drug:Temferon-001 Temferon
Drug:Temferon-001 Temferon
Diseases:Glioblastoma Multiforme
Diseases:Renal Cell Carcinoma
Date of Upcoming Event:2024-10-25
Name of Upcoming Event:Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective
Full Press ReleaseSEC FilingsOur GNTA Tweets

About Gravity Analytica

Recent News

  • 02.18.2025 - February 18, 2025 - February 20, 2025 : 6th Glioblastoma Drug Development Summit
  • 01.17.2025 - 6th Glioblastoma Drug Development Summit
  • 01.16.2025 - Rodman & Renshaw

Recent Filings

  • 12.30.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 12.20.2024 - 424B5 Prospectus [Rule 424(b)(5)]
PDF Version

MILANandNEW YORK,Oct. 23, 2024(GLOBE NEWSWIRE) --Genenta Science(NASDAQ: GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to theItaly-U.S.meeting“Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”scheduled at2.00 PMonOctober 25th, 2024at theU.S. Senate-Washington, D.C.The event is organized by theU.S. National Security Commission on Emerging Biotechnology(NSCEB) and theItalian Embassyin theU.S.

The upcoming mission to Washington, D.C. is part of the strategic plan of theItalian Working Group on the Internationalization of the Biotech Sector(NWTIB)established by the Deputy Prime Minister and Minister of Foreign AffairsAntonio Tajani. Pierluigi Paracchi, as a moderator of the NWTIB, will present the recently releasedInterim Report(full report in EnglishHERE).

Keynote Speakers:Michelle Rozo, Vice Chair of theNational Security Commission on Emerging Biotechnology(NSCEB)Mariangela Zappia, Ambassador ofItalyto theU.S.Megan Frisk, Ph.D., Director Division of lnternational Affairs at theAdvanced Research Projects Agency for Health(ARPA-H)Mauro Battocchi, Director General for the Promotion of ltaly at the ltalianMinistry of Foreign AffairsPierluigi Paracchi,CEO and Co-founder ofGenenta Science(Nasdaq: GNTA)Patrick Soon-Shiong,M.D.,Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman of ImmunityBio, Executive Chairman ofCalifornia TimesAndrea llly, Chair at lllycaffè

From the CEO's Desk: Pierluigi Paracchistated: “With the pandemic, biotechnologies have been elevated to strategic technologies by leading global nations.Italy, with its rich scientific heritage, must ensure that these innovations are rapidly and concretely applied, while preserving them as national assets. At the same time, the internationalization of the sector, collaboration with partner countries, and the attraction of foreign investments are crucial for ensuring competitive growth. Government investment agencies should focus on strategic operations of a competitive scale, aligning with the international standards of countries already leading the sector.”

Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective

About Genenta and TemferonGenenta (www.genenta.com) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell therapy for the treatment of a variety of solid tumor cancers. TemferonTM is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon is currently under investigation in a clinical trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter (uMGMT-GBM) and expects to commence a Phase 1 clinical trial for metastatic Renal Cell Carcinoma (mRCC). Temferon is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology.

Forward-Looking StatementsStatements in this press release contain “forward-looking statements,” within the meaning of theU.S.Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of its ongoing clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its expected clinical trial for metastatic RCC or any related studies, as well as Genenta’s ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year endedDecember 31, 2023filed with theSecurities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law.

Genenta MediaTiziana Pollio, Mobile: +39 348 23 15 143Email:tiziana.pollio@genenta.com

A photo accompanying this announcement is available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/0eb35962-e4cc-415b-8ed7-30daa2c62281

Primary Logo

Agenda

Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective

Source: GENENTA SCIENCE SPA

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com